BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25119013)

  • 1. Primary mucinous cystadenocarcinoma of the breast with amplification of the HER2 gene confirmed by FISH - case report and review of the literature.
    Kucukzeybek BB; Yigit S; Sari AA; Rezanko T; Durak E; Sadullahoglu C
    Pol J Pathol; 2014 Mar; 65(1):70-3. PubMed ID: 25119013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucinous cystadenocarcinoma of the breast with amplification of the HER2-gene confirmed by FISH: The first case reported.
    Petersson F; Pang B; Thamboo TP; Putti TC
    Hum Pathol; 2010 Jun; 41(6):910-3. PubMed ID: 20338619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast.
    Latta EK; Tjan S; Parkes RK; O'Malley FP
    Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
    Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
    Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
    Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
    Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous cystadenocarcinoma of the breast: a new entity with broad differentials-a case report.
    Kaur K; Shah A; Gandhi J; Trivedi P
    J Egypt Natl Canc Inst; 2022 Feb; 34(1):9. PubMed ID: 35224708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of HER2/neu status: a pilot study comparing HER2/neu dual in situ hybridization DNA probe cocktail assay performed on cell blocks to immunohistochemisty and fluorescence in situ hybridization performed on histologic specimens.
    Hartman AK; Gorman BK; Chakraborty S; Mody DR; Schwartz MR
    Arch Pathol Lab Med; 2014 Apr; 138(4):553-8. PubMed ID: 24678687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer Signature Investigation: ERBB2 (HER2)-Activating Mutation and Amplification-Positive Breast Carcinoma Mimicking Lung Primary.
    Shih J; Bashir B; Gustafson KS; Andrake M; Dunbrack RL; Goldstein LJ; Boumber Y
    J Natl Compr Canc Netw; 2015 Aug; 13(8):947-52. PubMed ID: 26285240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2-positive pure mucinous breast carcinoma: A case report and literature review.
    Zhao X; Yang X; Gao R; Zhai L; Yang L; Yu K
    Medicine (Baltimore); 2020 Aug; 99(33):e20996. PubMed ID: 32871976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
    Press MF; Bernstein L; Thomas PA; Meisner LF; Zhou JY; Ma Y; Hung G; Robinson RA; Harris C; El-Naggar A; Slamon DJ; Phillips RN; Ross JS; Wolman SR; Flom KJ
    J Clin Oncol; 1997 Aug; 15(8):2894-904. PubMed ID: 9256133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical (IHC) HER-2/neu and fluorescent-in situ hybridization (FISH) gene amplification of breast cancer in Indian women.
    Singhai R; Patil V; Patil A
    Asian Pac J Cancer Prev; 2011; 12(1):179-83. PubMed ID: 21517254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of HER-2/neu gene amplification in breast carcinomas using quantitative real-time PCR - a comparison with immunohistochemical and FISH results.
    Kulka J; Tôkés AM; Kaposi-Novák P; Udvarhelyi N; Keller A; Schaff Z
    Pathol Oncol Res; 2006; 12(4):197-204. PubMed ID: 17189981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular protocol for HER2/neu analysis in breast carcinoma].
    Artufel MV; Valero AC; Lladó RR; Sagalés NE; Llorca MC; Carazo AM; Cardó CC; Torrus XP
    Clin Transl Oncol; 2005 Dec; 7(11):504-11. PubMed ID: 16373062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.
    Ariga R; Zarif A; Korasick J; Reddy V; Siziopikou K; Gattuso P
    Breast J; 2005; 11(4):278-80. PubMed ID: 15982396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R; Mulligan AM; Have C; O'Malley FP
    Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):316-24. PubMed ID: 17721278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization.
    Santin AD; Bellone S; Van Stedum S; Bushen W; De Las Casas LE; Korourian S; Tian E; Roman JJ; Burnett A; Pecorelli S
    Gynecol Oncol; 2005 Jul; 98(1):24-30. PubMed ID: 15894362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu Oncogene Amplification by Fluorescence In Situ Hybridization and Protein Overexpression on Immunohistochemistry in Breast Cancer.
    Lateef F; Jamal S; Nasir S
    J Coll Physicians Surg Pak; 2018 Aug; 28(8):581-585. PubMed ID: 30060783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER-2 gene amplification by fluorescence in situ hybridization (FISH) compared with immunohistochemistry (IHC) in breast cancer: a study of 528 equivocal cases.
    Zhang H; Ren G; Wang X; Zhao J; Yao H; Bai Y; Bo W
    Breast Cancer Res Treat; 2012 Jul; 134(2):743-9. PubMed ID: 22678158
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).
    Fritzsche FR; Bode PK; Moch H; Kristiansen G; Varga Z; Bode B
    Am J Surg Pathol; 2010 Aug; 34(8):1180-5. PubMed ID: 20661016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.